Gene therapy with recombinant adeno-associated vectors for neovascular age-related macular degeneration: 1 year follow-up of a phase 1 randomised clinical trial

BACKGROUND Neovascular, or wet, age-related macular degeneration causes central vision loss and represents a major health problem in elderly people, and is currently treated with frequent intraocular injections of anti-VEGF protein. Gene therapy might enable long-term anti-VEGF therapy from a single treatment. We tested the safety of rAAV.sFLT-1 in treatment of wet age-related macular degeneration with a single subretinal injection. METHODS In this single-centre, phase 1, randomised controlled trial, we enrolled patients with wet age-related macular degeneration at the Lions Eye Institute and the Sir Charles Gairdner Hospital (Nedlands, WA, Australia). Eligible patients had to be aged 65 years or older, have age-related macular degeneration secondary to active subfoveal choroidal neovascularisation, with best corrected visual acuity (BCVA) of 3/60-6/24 and 6/60 or better in the other eye. Patients were randomly assigned (3:1) to receive either 1 × 10(10) vector genomes (vg; low-dose rAAV.sFLT-1 group) or 1 × 10(11) vg (high-dose rAAV.sFLT-1 group), or no gene-therapy treatment (control group). Randomisation was done by sequential group assignment. All patients and investigators were unmasked. Staff doing the assessments were masked to the study group at study visits. All patients received ranibizumab at baseline and week 4, and rescue treatment during follow-up based on prespecified criteria including BCVA measured on the Early Treatment Diabetic Retinopathy Study (EDTRS) scale, optical coherence tomography, and fluorescein angiography. The primary endpoint was ocular and systemic safety. This trial is registered with ClinicalTrials.gov, number NCT01494805. FINDINGS From Dec 16, 2011, to April 5, 2012, we enrolled nine patients of whom eight were randomly assigned to receive either intervention (three patients in the low-dose rAAV.sFLT-1 group and three patients in the high-dose rAAV.sFLT-1 group) or no treatment (two patients in the control group). Subretinal injection of rAAV.sFLT-1 was highly reproducible. No drug-related adverse events were noted; procedure-related adverse events (subconjunctival or subretinal haemorrhage and mild cell debris in the anterior vitreous) were generally mild and self-resolving. There was no evidence of chorioretinal atrophy. Clinical laboratory assessments generally remained unchanged from baseline. Four (67%) of six patients in the treatment group required zero rescue injections, and the other two (33%) required only one rescue injection each. INTERPRETATION rAAV.sFLT-1 was safe and well tolerated. These results support ocular gene therapy as a potential long-term treatment option for wet age-related macular degeneration. FUNDING National Health and Medical Research Council of Australia, Richard Pearce Bequest, Lions Save Sight Foundation, Brian King Fellowship, and Avalanche Biotechnologies, Inc.

[1]  J. Bennett,et al.  Novel AAV serotypes for improved ocular gene transfer , 2008, The journal of gene medicine.

[2]  Paul P. Lee,et al.  Intraocular pressure in eyes receiving monthly ranibizumab in 2 pivotal age-related macular degeneration clinical trials. , 2014, Ophthalmology.

[3]  Dean Y. Li,et al.  Photoreceptor avascular privilege is shielded by soluble VEGF receptor-1 , 2013, eLife.

[4]  P. D. de Jong,et al.  Increased expression of angiogenic growth factors in age-related maculopathy , 1997, The British journal of ophthalmology.

[5]  L. Aiello,et al.  RISKS OF INTRAVITREOUS INJECTION: A COMPREHENSIVE REVIEW , 2004, Retina.

[6]  N. Bressler,et al.  CEREBROVASCULAR ACCIDENTS IN PATIENTS TREATED FOR CHOROIDAL NEOVASCULARIZATION WITH RANIBIZUMAB IN RANDOMIZED CONTROLLED TRIALS , 2012, Retina.

[7]  G. Vrensen,et al.  Vascular endothelial growth factors and angiogenesis in eye disease , 2003, Progress in Retinal and Eye Research.

[8]  O Ouchterlony,et al.  A solid-phase enzyme-linked immunospot (ELISPOT) assay for enumeration of specific antibody-secreting cells. , 1983, Journal of immunological methods.

[9]  Joan W. Miller,et al.  Age-related macular degeneration. , 2008, The New England journal of medicine.

[10]  Christian Simader,et al.  Evaluation of optical coherence tomography findings in age-related macular degeneration: a reproducibility study of two independent reading centres , 2008, British Journal of Ophthalmology.

[11]  F. Cremers,et al.  Retinal gene therapy in patients with choroideremia: initial findings from a phase 1/2 clinical trial , 2014, The Lancet.

[12]  P. Campochiaro,et al.  Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: results of a phase I clinical trial. , 2006, Human gene therapy.

[13]  Glenn J Jaffe,et al.  Growth of geographic atrophy in the comparison of age-related macular degeneration treatments trials. , 2015, Ophthalmology.

[14]  D. Hinton,et al.  Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. , 1996, Investigative ophthalmology & visual science.

[15]  N. Bouck PEDF: anti-angiogenic guardian of ocular function. , 2002, Trends in molecular medicine.

[16]  Nick Tyler,et al.  Effect of gene therapy on visual function in Leber's congenital amaurosis. , 2008, The New England journal of medicine.

[17]  William J Feuer,et al.  Gene therapy for leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 years. , 2012, Archives of ophthalmology.

[18]  Gerald Liew,et al.  Ranibizumab for neovascular age-related macular degeneration. , 2007, The New England journal of medicine.

[19]  R. Nuzzi,et al.  Local and Systemic Complications after Intravitreal Administration of Anti-Vascular Endothelial Growth Factor Agents in the Treatment of Different Ocular Diseases: A Five-Year Retrospective Study , 2015, Seminars in ophthalmology.

[20]  F. Rolling,et al.  Biodistribution of rAAV vectors following intraocular administration: evidence for the presence and persistence of vector DNA in the optic nerve and in the brain. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[21]  I. Morita,et al.  Novel mechanism for age‐related macular degeneration: An equilibrium shift between the angiogenesis factors VEGF and PEDF , 2001, Journal of cellular physiology.

[22]  P. Campochiaro,et al.  Regression of choroidal neovascularization results in macular atrophy in anti-vascular endothelial growth factor-treated eyes. , 2015, American journal of ophthalmology.

[23]  G. Ying,et al.  Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. , 2012, Ophthalmology.

[24]  R. Kendall,et al.  Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[25]  Usha Chakravarthy,et al.  Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial , 2013, The Lancet.

[26]  U. Schmidt-Erfurth Clinical safety of ranibizumab in age-related macular degeneration , 2010, Expert opinion on drug safety.

[27]  J. Vander,et al.  Ranibizumab for Predominantly Classic Neovascular Age-related Macular Degeneration: Subgroup Analysis of First-year ANCHOR Results , 2008 .

[28]  Botond Roska,et al.  Gene therapy for blindness. , 2013, Annual review of neuroscience.

[29]  G. Ying,et al.  Growth of geographic atrophy in the comparison of age-related macular degeneration treatments trials. , 2015, Ophthalmology.

[30]  Gerard Mimoun,et al.  CHANGES IN VISUAL ACUITY IN PATIENTS WITH WET AGE-RELATED MACULAR DEGENERATION TREATED WITH INTRAVITREAL RANIBIZUMAB IN DAILY CLINICAL PRACTICE: The LUMIERE Study , 2013, Retina.

[31]  Jean Bennett,et al.  Nonhuman primate models for diabetic ocular neovascularization using AAV2-mediated overexpression of vascular endothelial growth factor. , 2005, Diabetes.

[32]  Ying Liu,et al.  Clinical utilization of anti-VEGF agents and disease monitoring in neovascular age-related macular degeneration. , 2014, American journal of ophthalmology.

[33]  R. Klein,et al.  Causes and prevalence of visual impairment among adults in the United States. , 2004, Archives of ophthalmology.

[34]  R. Guymer,et al.  Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study. , 2011, Ophthalmology.

[35]  E. Rakoczy,et al.  rAAV.sFlt-1 gene therapy achieves lasting reversal of retinal neovascularization in the absence of a strong immune response to the viral vector. , 2009, Investigative Ophthalmology and Visual Science.

[36]  Manju Patel,et al.  Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. , 2006, Ophthalmology.

[37]  G. Veres,et al.  Preclinical safety evaluation of AAV2-sFLT01- a gene therapy for age-related macular degeneration. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[38]  I J Constable,et al.  Preclinical safety evaluation of subretinal AAV2.sFlt-1 in non-human primates , 2011, Gene Therapy.

[39]  Paul P. Lee,et al.  Ocular complications after anti-vascular endothelial growth factor therapy in Medicare patients with age-related macular degeneration. , 2011, American journal of ophthalmology.

[40]  Kathleen A. Marshall,et al.  AAV2 Gene Therapy Readministration in Three Adults with Congenital Blindness , 2012, Science Translational Medicine.

[41]  R. Guymer,et al.  The SECURE study: long-term safety of ranibizumab 0.5 mg in neovascular age-related macular degeneration. , 2013, Ophthalmology.

[42]  Kang Zhang,et al.  Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). , 2013, Ophthalmology.

[43]  I. Constable,et al.  Long-term evaluation of AAV-mediated sFlt-1 gene therapy for ocular neovascularization in mice and monkeys. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[44]  P. Campochiaro,et al.  Re: Grunwald et al.: risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials (ophthalmology 2014;121:150-61). , 2014, Ophthalmology.

[45]  W. Freeman,et al.  HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration. , 2012, Ophthalmology.

[46]  William J Feuer,et al.  An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. , 2007, American journal of ophthalmology.

[47]  C. Regillo,et al.  Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. , 2008, American journal of ophthalmology.

[48]  P. Rakoczy,et al.  Potential long-term inhibition of ocular neovascularisation by recombinant adeno-associated virus-mediated secretion gene therapy , 2002, Gene Therapy.

[49]  Ivana K. Kim,et al.  Inhibition of choroidal neovascularization in a nonhuman primate model by intravitreal administration of an AAV2 vector expressing a novel anti-VEGF molecule. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[50]  D. Moshfeghi,et al.  Ocular hypertension and intraocular pressure asymmetry after intravitreal injection of anti-vascular endothelial growth factor agents. , 2013, Ophthalmic surgery, lasers & imaging retina.

[51]  Glenn J Jaffe,et al.  Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. , 2014, Ophthalmology.